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Tumors are complex masses containing not just neoplastic cells but also stromal cells, neovasculature, and
a gamut of immune cells. In this issue, Bindea et al. (2013) identify a surprising new ‘‘immune landscape’’
associated with prolonged disease-free survival.The amount of data that is available to
every member of society with a high-
speed Internet connection has increased
at such a rate that it boggles the mind.
One recent estimate is that the amount of
data coursing through the global Internet
in2013will amount tomore than500billion
gigabytes of information. This represents
an increase of 10-fold over the the amount
of data in the past 5 years alone. This ‘‘Big
Data Revolution’’ is likely to affect fields as
diverse as weather forecasting and crime
fighting, and the conduct of immunobiol-
ogy is certainly no exception.
Bindea et al. (2013) have used this new-
found ability to generate and to manipu-
late large amounts of data from varieties
of sources to cast new light on the
tumor microenvironment. In this issue of
Immunity, they offer an extraordinarily
high-resolution view of the immune cells
found within surgically excised tumor
masses.
It has long been appreciated that estab-
lished tumors are complex masses that
contain not only neoplastic cells but also
nontransformed cellular elements such
as stromal cells, the neovasculature, and
a gamut of immune cells. Tumor masses
have been compared to rogue organ sys-
tems that are comprised of collections of
cells that compete with each other and
with normal tissue in a Darwinian struggle
for survival (Khong and Restifo, 2002).
The complexity of these constantly
evolving systems is apparent, and eluci-
dating all of the cellular constituents—
let alone their interactions with each
other—is well out of reach of even the
most sophisticated teams of pathologists.
Human tumors are triggered by amyriad
of causes and evolve over periods
measured in years and decades, and
they are not easily modeled in animals.
Individual scientists pursuing reductionistapproaches can provide informative narra-
tives about particular cells, pathways, and
molecules,buta full andunbiasedembrace
of thecomplexityof thehumansystempro-
vides a much-needed bird’s-eye view of
this ongoing research. The development
of high-throughput techniques such as
whole-genome analysis, multicolor immu-
nohistochemistry, and multiparameter
flow cytometry—along with the bioinfor-
matics tools useful for analyzing the resul-
tant data—has put a high-resolution view
of tumor complexity within reach.
Previous work from Galon’s group has
elucidated the major importance of cyto-
toxic and memory T cells in determining
disease-free survival in cohorts of patients
(Galon et al., 2006; Page`s et al., 2005). The
authors have cogently argued that a pa-
tient’s ‘‘immunoscore,’’ based on the
quantification of specific patterns of im-
mune activation in the tumor microenvi-
ronment, can yield information that is high-
ly associated with patient prognosis.
Currently, patients with colorectal cancer
are usually given prognoses based on a
staging system established by the Amer-
ican Joint Committee on Cancer (AJCC).
This system is called the TNM system (for
tumors, nodes, metastases) because it
employs measurements such as the de-
gree of invasion of the intestinal wall, the
amount of tumor involvement of nearby
lymphatic structures, and the presence
or absence of distant metastases, to
assign patients to stages, numbered I–IV.
However, reports from the Galon group
have used Cox multivariate analysis to
claim that thepredictive valueof the immu-
noscore exceeds that of the TNM system
currently in place (Mlecnik et al., 2011).
These data are consistent with a
plethora of observations from other
studies (Fridman et al., 2012), and in addi-
tion, they fit with findings that clinicallyImmunity 39effective immunotherapies to date all
depend on these endogenous T cells.
Approaches to cancer immunotherapy
that result in objective tumor regressions
include the adoptive transfer of tumor-
infiltrating lymphocytes (Restifo et al.,
2012) as well as antibodies to immune
‘‘checkpoints’’CTLA4andPD1-PDL1 (To-
palian et al., 2012; van Elsas et al., 2001).
Here, Bindea et al. (2013) use systems-
biology approaches to quantify 28 dif-
ferent immune cell subpopulations (both
innate and adaptive) in situ in human
tumors. This approach relies on ana-
lysis of whole-genome expression; the
analysis is backed up with PCR arrays,
multicolored immunohistochemistry, and
even mouse models. The authors have
previously identified the importance of
cytotoxic and memory T cells, but what is
substantially new in the present data set
is the addition of key roles identified for T
follicular helper (Tfh) and B cells via micro-
arrays and immunohistochemistry, and
these new data add significantly to the
alogorithms used for predicting patient
disease-free survival. These particular im-
mune cells are identified and quantified
with a set of leukocyte-subset-specific
signature genes that were obtained by
theuseof highlypurified, flow-sortedcells.
The authors confirmed these data by us-
ing highly sensitive quantitative PCR to
further investigate the expression of 81
relatively cell-specific genes, most of
them encoding membrane receptors, to
study 153 patients with colorectal cancer.
Using this approach, the authors found
that the genes identifying the ‘‘adaptive im-
mune clusters,’’ defined here as T, B, and
Tfh cells, were highly correlated with
patient disease-free survival. Specifically,
patients with elevations in genes related
to MHC-II, B cell costimulation, T cells,
and Tfh cells experienced increased, October 17, 2013 ª2013 Elsevier Inc. 631
Figure 1. Immune Cells in a Tumor
Tumormasses are complexmixtures of cells that contain stromal cells, vasculature, and awide array of im-
mune cells. An unsupervised correlation matrix of the intra-tumor ‘‘immunome’’ reveals that, of the 28 cell
types that were specifically analyzed, CTL, Tfh, and B cells (shown in bold) had the strongest correlations
with increased disease-free survival, and these cell types were furthermore correlated with each other.
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Previewssurvival, whereas there was no significant
correlation with MHC-I- and inflam-
mation-related genes. Furthermore, the
expression of markers for Tfh cells and
that of markers for B cells were correlated
with each other in an unsupervised anal-
ysis. Importantly, the pattern changed
over time. With the exception of Tfh cells,
most T cell subpopulations marked by
CD8, CD45RO, CD57, and FOXP3 ebbed
with tumor progression. In contrast, the
density of B cells increased with tumor
stage, as did the density of innate immune
cells such as neutrophils, mast cells, iDCs,
pDCs, and macrophages.
Underpinning the current conclusions
was the finding that one chemokine in
particular, CXCL13, and one cytokine, IL-
21, were found to be critical and positively
correlated with disease-free survival.
Critics might complain that these conclu-
sions are based on vignettes of large
amounts of primary data, and still unre-
solved is the clear and rigorous delineation
of a ‘‘training set’’ and a ‘‘test set.’’ Despite
these shortcomings, the authors deploy
considerable bioinformatic and statistical
knowhow in the form of their CluePedia
and ClueGO software (Bindea et al.,
2013).More importantly for immunologists,
they also show how themajor components
of their findings exist in plausible immune
networks (Figure 1). In addition, the authors
find that a tumor mechanism (chromo-
somal deletion of CXCL13) is associated
with a decrease in CXCL13 production
and decreased densities of Tfh and B cells.
Patients with more Th17 cells trended
toward having a worse prognosis. It was632 Immunity 39, October 17, 2013 ª2013 Elperhaps striking that there was a notable
lack of evidence in these new data sets
for a major negative role of immune cell
subsets that classically mediate immuno-
suppression. For example, T regulatory
cells were not predictive in this data
set. Cells that might be designated
as myeloid-derived suppressor cells
(MDSCs), such as monocyte populations,
were not specifically looked at, although
neutrophils, macrophages and dendritic
cell subsets, each of which might have
components deemed to be MDSCs, were
notably absent as prognostic predictors.
Thus, these negative cellular influences
did not proclaim themselves as predictors
of negative outcomes in these patient co-
horts, a surprising finding given the wealth
of data indicating the importance of
cellular immunosuppression in the tumor
microenvironment in animal models.
The authors assemble a large amount of
information in an effort to visualize the ‘‘im-
mune landscapes’’ that are associated
with progression and recurrence of colo-
rectal cancer in their patient cohorts.
Changes in the immune landscape help
us to understand the evolution of the
immune response that theauthorsobserve
with tumor progression. Given these new
findings,onemightconclude that immuno-
therapies involving Tfh cells and IL-21
might be of great interest. Based on recent
work from a diversity of research labora-
tories, these suggestions are intriguing.
Tfh cells are a CD4+ T cell subset that
constitutively expresses CXCR5, a G
protein-coupled seven-transmembrane
receptor for CXCL13 (the central chemo-sevier Inc.kine identified in this analysis). Tfh cells
might be involved in the formation of
secondary lymphoid structures that can
be visualized in some human tumor
samples.Tfhcells also trigger thesecretion
of IL-21, a key component of the immune
signature found here. In addition to helping
to form follicular structures, IL-21 through
its action via STAT3 might be critical in re-
taining tumor-stimulated CD8+ T cells in
less-differentiated and more potent states
(Hinrichs et al., 2008).
There seems little doubt that careful
quantification of tumor-infiltrating im-
mune cells can help determine a patient’s
prognosis in colorectal cancer, and
this alone represents a major advance. It
is still too early to know whether this
detailed information about the tumor
immune microenvironment can be used
to guide the treatment of patients with
cancer. Nevertheless, ‘‘big data’’—care-
fully crunched with innovative software
tools—might ultimately serve as a great
illuminator of the biology of the antitumor
response and thus spur new and more
effective cancer immunotherapies.
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